In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.09 below Galectin Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 427 other companies have achieved higher Quick Ratio than Galectin Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1278 to 3849.

Explain Quick Ratio?
How much Cash & cash equivalents GALT�s has?
What are GALT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GALT/financial-strength

https://api.csimarket.com/api/v1/companies/GALT/fundamentals

https://api.csimarket.com/api/v1/companies/GALT/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

GALT Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	1307.27 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-3.6 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.09	Subscribe	Subscribe	Subscribe	Subscribe
GALT's Total Ranking	# 3849	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	1974.98 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-5.92 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 428
Healthcare Sector	# 860
Overall Market	# 3849

Quick Ratio Statistics
High	Average	Low
149.88	15.22	0.07
(Jun 30 2020)		(Mar 31 2025)

Financial Statements
Galectin Therapeutics Inc 's Current Liabilities	$ 152 Millions	Visit GALT's Balance sheet
Galectin Therapeutics Inc 's Cash & cash equivalent	$ 13 Millions	Visit GALT's Balance sheet
Source of GALT's Sales		Visit GALT's Sales by Geography

Cumulative Galectin Therapeutics Inc 's Quick Ratio

GALT's Quick Ratio for the trailling 12 Months

GALT Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	76.6 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-10.64 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.19	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2348	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	86.68 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-0.87 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to GALT Financial Strength Comparisons >> Go to Compare GALT Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $151.62 millions, cumulative Quick Ratio decreased to 0.19 below the Galectin Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Galectin Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 4081 to 4094.

Explain Quick Ratio?
How much Cash & cash equivalents GALT�s has?
What are GALT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 910
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
28.96	7.15	0.16
(Mar 31 2020)		(Sep 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Teva Pharmaceutical Industries Limited	0.23	$ 3,655.000 Millions	$ 15,646.000 Millions
Cytodyn inc	0.22	$ 11.852 Millions	$ 53.727 Millions
Collegium Pharmaceutical Inc	0.22	$ 129.467 Millions	$ 589.861 Millions
International Stem Cell Corporation	0.22	$ 1.089 Millions	$ 4.984 Millions
Earth Science Tech Inc	0.22	$ 0.631 Millions	$ 2.902 Millions
Viatris Inc	0.22	$ 1,368.700 Millions	$ 6,345.800 Millions
Eli Lilly And Company	0.19	$ 8,950.000 Millions	$ 47,741.000 Millions
Polomar Health Services, Inc.	0.18	$ 0.188 Millions	$ 1.063 Millions
Tempest Therapeutics Inc	0.18	$ 0.779 Millions	$ 4.450 Millions
Abbvie Inc	0.16	$ 6,569.000 Millions	$ 41,642.000 Millions
Amneal Pharmaceuticals Inc	0.15	$ 136.280 Millions	$ 883.187 Millions
Neonc Technologies Holdings Inc	0.15	$ 3.573 Millions	$ 23.507 Millions
Jaguar Health Inc	0.15	$ 3.788 Millions	$ 25.380 Millions
Alaunos Therapeutics Inc	0.14	$ 0.124 Millions	$ 0.864 Millions
Cumberland Pharmaceuticals Inc	0.11	$ 3.862 Millions	$ 35.193 Millions
Igc Pharma Inc	0.11	$ 0.354 Millions	$ 3.287 Millions
Tuhura Biosciences Inc	0.11	$ 0.996 Millions	$ 9.255 Millions
Gridai Technologies Corp	0.10	$ 1.380 Millions	$ 14.146 Millions
Bioxcel Therapeutics Inc	0.09	$ 12.841 Millions	$ 137.149 Millions
Lunai Bioworks Inc	0.09	$ 1.714 Millions	$ 18.910 Millions
Galectin Therapeutics Inc	0.09	$ 13.275 Millions	$ 151.619 Millions
Lftd Partners Inc	0.08	$ 0.304 Millions	$ 3.648 Millions
Processa Pharmaceuticals Inc	0.08	$ 0.196 Millions	$ 2.387 Millions
Vogenx, Inc.	0.06	$ 0.193 Millions	$ 3.188 Millions
Cv Sciences Inc	0.05	$ 0.266 Millions	$ 4.943 Millions
Citius Pharmaceuticals Inc	0.05	$ 17.008 Millions	$ 333.952 Millions
Sunshine Biopharma Inc	0.05	$ 0.281 Millions	$ 5.619 Millions
Hcw Biologics Inc	0.04	$ 0.741 Millions	$ 18.648 Millions
China Pharma Holdings Inc	0.04	$ 0.305 Millions	$ 7.682 Millions
Bioxytran Inc	0.03	$ 0.177 Millions	$ 5.275 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.